New drug treatments for Osteoarthritis: What is on the horizon?
Osteoarthritis (OA) is the most common form of arthritis, yet has historically lagged far behind rheumatoid arthritis in terms of drug development. Despite the many challenges presented by clinical trials in OA, improvements in our understanding of disease pathogenesis and a move to treat pain, as w...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
European Medical Journal
2016
|
| _version_ | 1797104751543844864 |
|---|---|
| author | Watt, FE Gulati, M |
| author_facet | Watt, FE Gulati, M |
| author_sort | Watt, FE |
| collection | OXFORD |
| description | Osteoarthritis (OA) is the most common form of arthritis, yet has historically lagged far behind rheumatoid arthritis in terms of drug development. Despite the many challenges presented by clinical trials in OA, improvements in our understanding of disease pathogenesis and a move to treat pain, as well as underlying disease process, mean there are now many new pharmacological therapies currently in various stages of clinical trials. The medical need for these therapies and the evidence for recent tissue and molecular targets are reviewed. Current therapeutic examples in each area are discussed, including both novel therapeutics and existing agents which may be repurposed from other disease areas. Some challenges remain, but opportunities for improving symptoms and disease process in OA in the clinic with new pharmacological agents would appear to be on the close horizon. |
| first_indexed | 2024-03-07T06:37:58Z |
| format | Journal article |
| id | oxford-uuid:f84e8c4a-8a82-412d-b970-48d95edb4f22 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:37:58Z |
| publishDate | 2016 |
| publisher | European Medical Journal |
| record_format | dspace |
| spelling | oxford-uuid:f84e8c4a-8a82-412d-b970-48d95edb4f222022-03-27T12:49:14ZNew drug treatments for Osteoarthritis: What is on the horizon?Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f84e8c4a-8a82-412d-b970-48d95edb4f22EnglishSymplectic Elements at OxfordEuropean Medical Journal2016Watt, FEGulati, MOsteoarthritis (OA) is the most common form of arthritis, yet has historically lagged far behind rheumatoid arthritis in terms of drug development. Despite the many challenges presented by clinical trials in OA, improvements in our understanding of disease pathogenesis and a move to treat pain, as well as underlying disease process, mean there are now many new pharmacological therapies currently in various stages of clinical trials. The medical need for these therapies and the evidence for recent tissue and molecular targets are reviewed. Current therapeutic examples in each area are discussed, including both novel therapeutics and existing agents which may be repurposed from other disease areas. Some challenges remain, but opportunities for improving symptoms and disease process in OA in the clinic with new pharmacological agents would appear to be on the close horizon. |
| spellingShingle | Watt, FE Gulati, M New drug treatments for Osteoarthritis: What is on the horizon? |
| title | New drug treatments for Osteoarthritis: What is on the horizon? |
| title_full | New drug treatments for Osteoarthritis: What is on the horizon? |
| title_fullStr | New drug treatments for Osteoarthritis: What is on the horizon? |
| title_full_unstemmed | New drug treatments for Osteoarthritis: What is on the horizon? |
| title_short | New drug treatments for Osteoarthritis: What is on the horizon? |
| title_sort | new drug treatments for osteoarthritis what is on the horizon |
| work_keys_str_mv | AT wattfe newdrugtreatmentsforosteoarthritiswhatisonthehorizon AT gulatim newdrugtreatmentsforosteoarthritiswhatisonthehorizon |